22 May 2013
Keywords: acambis, je, vacc, meets, ph, iii, efficacy
Article | 12 March 2007
UK-based vaccines developer Acambis says that its single-dose Japanese encephalitis vaccine ChimeriVax has met the primary immunogenecity
endpoint in a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
6 November 2006
21 May 2013
© 2013 thepharmaletter.com